Bing

SEARCH HISTORY

Amarin Co. plc (NASDAQ:AMRN) traded down 0.46% on Tuesday, reaching $2.15. 596,090 shares of the company’s stock traded hands. The stock has a 50-day moving average of $2.40 and a 200 day moving average of $1.99. Amarin Co. plc has a 52 …
Ticker Report · 15 hours ago
Biotech stock Amarin Corporation plc (ADR) (NASDAQ:AMRN) has been quite the conversation piece lately, and for good reason. Following a major analyst upgrade from HC Wainwright a couple weeks ago, we saw tremendous gains in Amarin stock
Investor Place · 3/23/2015
Amarin Corporation plc (AMRN) shares are up more than 14% to $2.72 in early trading. The move comes on a big volume too with the issue currently trading more than 13.6 million shares, compared to the average volume of 4.4 million shares. The stock
Wall Street Pit · 3/18/2015
More from Bing News
Investors in Amarin Corp plc (AMRN) saw new options become available today, for the August 14th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the AMRN options chain for the new August 14th contracts and …
The Street · 7/2/2015
Investors in Amarin Corp plc (NASD: AMRN) saw new options become available today, for the October 11th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the AMRN options chain for the new October 11th contracts …
Forbes · 10/3/2013
Amarin Corporation plc (AMRN - Snapshot Report) was a big mover last session ... This breaks the recent trend of the company as the stock is now trading above the volatile price range of $1.85–$2.07 in the past one-month time frame.
ZACKS · 5/29/2015
Still, no sign of new chemical entity (NCE) status by FDA; no partnership or buyout has materialized; and the stock is hovering near pre-clinical trial result levels. However, before being too short-sided, let's quickly review some of AMRN's strengths from ...
Seeking Alpha · 3/6/2013
One stock that might be an intriguing choice for investors right now is Amarin Corporation plc (AMRN). This is because this security in the medical space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry ...
Yahoo Finance · 9/3/2014
One stock that might be an intriguing choice for investors right now is Amarin Corporation plc ( AMRN). This is because this security in the Medical - Biomed/Genetics space is seeing solid earnings estimate revision activity, and is in great company from a ...
NASDAQ · 4/9/2015
Amarin Co. plc (NASDAQ:AMRN)‘s stock had its “hold” rating reissued by Zacks in a report released on Friday. Zacks’ analyst wrote, “Amarin Corporation plc is a global pharmaceutical group which develops innovative pharmaceutical products …
sleekmoney.com · 5/2/2015

Amarin Corporation

Company
Amarin Corporation is a biopharmaceutical company headquartered in Bedminster, New Jersey. The company develops and markets me…
Amarin Corporation is a biopharmaceutical company headquartered in Bedminster, New Jersey. The company develops and markets medicines for the treatment of cardiovascular disease. Amarin develops the drug Vascepa which is a prescription grade omega-3 fatty acid. In December 2007, the company acquired Ester Neurosciences Limited for 8.1 million USD. Amarin CEO Joe Zakrzewski has said that the company would like to first work on building its infrastructure out to commercialize the drug in the United States. Recently on July 26, 2012, their lead-candidate drug named Vascepa received FDA-approval. Vascepa will also be a key competitor against GlaxoSmithKline's Lovaza.
Data from: Wikipedia